Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

1.860 +0.080 (+4.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 183,114
Open 1.770
Bid (Size) 1.800 (500)
Ask (Size) 1.960 (1,000)
Prev. Close 1.780
Today's Range 1.770 - 1.950
52wk Range 1.640 - 39.92
Shares Outstanding 417,247,333
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill

Performance

YTD
-73.5%
-73.5%
1 Month
-58.6%
-58.6%
3 Month
-68.3%
-68.3%
6 Month
-67.7%
-67.7%
1 Year
-93.8%
-93.8%

More News

Read More
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026
From Berger Montague
Via GlobeNewswire
News headline image
SKYE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SKYE BIOSCIENCE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
NASDAQ: SKYE INVESTOR ALERT: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors of a January 16, 2026 Deadline
From Berger Montague
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Via Chartmill

Frequently Asked Questions

Is Skye Bioscience, Inc. - Common Stock publicly traded?
Yes, Skye Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Skye Bioscience, Inc. - Common Stock trade on?
Skye Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Skye Bioscience, Inc. - Common Stock?
The ticker symbol for Skye Bioscience, Inc. - Common Stock is SKYE on the Nasdaq Stock Market
What is the current price of Skye Bioscience, Inc. - Common Stock?
The current price of Skye Bioscience, Inc. - Common Stock is 1.860
When was Skye Bioscience, Inc. - Common Stock last traded?
The last trade of Skye Bioscience, Inc. - Common Stock was at 09/04/26 04:00 PM ET
What is the market capitalization of Skye Bioscience, Inc. - Common Stock?
The market capitalization of Skye Bioscience, Inc. - Common Stock is 776.08M
How many shares of Skye Bioscience, Inc. - Common Stock are outstanding?
Skye Bioscience, Inc. - Common Stock has 776M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.